Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, according to findings released by the company Thursday, adding to earlier findings indicating the medication is effective in preventing the spread of the disease.

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The data sets the stage for likely FDA approval of Lenacapavir for HIV prevention. Shares rose 3% in premarket trading.

Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.